AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2122710 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving taurine)
Number of subjects: 34
Study 211011 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal administration of 500 μg of fenoterol
Number of subjects: 10
Study 211011 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 200 μg of fenoterol
Number of subjects: 10
Study 211011 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 400 μg of fenoterol
Number of subjects: 10
Study 211011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30636725 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual EMG biofeedback group (VSG)
Number of subjects: 36
Study 30636725 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination EMG‐controlled electrical stimulation with visual EMG biofeedback group (CBG)
Number of subjects: 36
Study 30636725 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTG)
Number of subjects: 36
Study 30636725 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG‐controlled electrical stimulation group (ESG)
Number of subjects: 36
Study 27268381 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin (100 μg IV)
Number of subjects: 300
Study 27268381 — intervention group
Group type: COMPARATOR
Intervention: Syntometrine (5 IU oxytocin + 0.2 mg ergometrine)
Number of subjects: 300
Study 26047975 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg TA-8995
Number of subjects: 364
Study 26047975 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg TA-8995
Number of subjects: 364
Study 26047975 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg TA-8995
Number of subjects: 364
Study 26047975 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg TA-8995
Number of subjects: 364
Study 26047975 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg TA-8995 plus 20 mg atorvastatin
Number of subjects: 364
Study 26047975 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg TA-8995 plus 10 mg rosuvastatin
Number of subjects: 364
Study 23702258 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 0
Study 23702258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21837785 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Number of subjects: 58
Study 21837785 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir
Number of subjects: 58
Study 21837785 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 58
Study 21837785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 19626540 — intervention group
Group type: EXPERIMENTAL
Intervention: CPA + IFN-alpha2
Number of subjects: 581
Study 19626540 — intervention group
Group type: COMPARATOR
Intervention: CPA
Number of subjects: 581
Study 19626540 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha2 maintenance
Number of subjects: 581
Study 19626540 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 581
Study 17259483 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide
Number of subjects: 266
Study 17259483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study 15227651 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal digital assessment
Number of subjects: 89
Study 15227651 — intervention group
Group type: COMPARATOR
Intervention: Dynamometric measurements
Number of subjects: 89
Study 15514501 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained (TR) group
Number of subjects: 20
Study 15514501 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS-stimulated cytokine production
Number of subjects: 20
Study 15514501 — intervention group
Group type: EXPERIMENTAL
Intervention: HI group (high TLR4 expression)
Number of subjects: 20
Study 15514501 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic resistance exercise training (2x wk for previous 24 months)
Number of subjects: 20
Study 11020676 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent practice plus periodic feedback
Number of subjects: 84
Study 11020676 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic feedback only
Number of subjects: 84
Study 11020676 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 84
Study 9218639 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Jen-Chung point for 15 min
Number of subjects: 20
Study 9218639 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20
Study 9218639 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 20
Study 8355929 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg recombinant human relaxin in 3% methylcellulose gel
Number of subjects: 40
Study 8355929 — intervention group
Group type: COMPARATOR
Intervention: gel only (placebo)
Number of subjects: 40
Study 3721942 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (100 mg, oral and i.v. administration)
Number of subjects: 6
Study 3721942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2675952 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0
Study 2675952 — intervention group
Group type: COMPARATOR
Intervention: Nitrazepam
Number of subjects: 0
Study 30971241 — intervention group
Group type: EXPERIMENTAL
Intervention: Late PMDI (periarticular multimodal drug injection) administered before prosthetic implantation
Number of subjects: 48
Study 30971241 — intervention group
Group type: EXPERIMENTAL
Intervention: Early PMDI (periarticular multimodal drug injection) administered just after knee arthrotomy
Number of subjects: 48
Study 30971241 — intervention group
Group type: COMPARATOR
Intervention: Both early and late PMDI
Number of subjects: 48
Study 27819756 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (GA) with prostatic calculi
Number of subjects: 212
Study 27819756 — intervention group
Group type: COMPARATOR
Intervention: Group B (GB) without prostatic calculi
Number of subjects: 212
Study 25872570 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement (arginine, glutamine, β-hydroxy β-methylbutyrate)
Number of subjects: 50
Study 25872570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 24113595 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand hygiene accountability program
Number of subjects: 109988
Study 24113595 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand hygiene adherence rates
Number of subjects: 109988
Study 21896129 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid-based emollient foam
Number of subjects: 20
Study 21896129 — intervention group
Group type: COMPARATOR
Intervention: Ceramide-containing emulsion cream
Number of subjects: 20
Study 19894420 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental intervention
Number of subjects: 0
Study 19894420 — intervention group
Group type: COMPARATOR
Intervention: Comparison intervention
Number of subjects: 0
Study 17607014 — intervention group
Group type: EXPERIMENTAL
Intervention: CpG ODNs
Number of subjects: 0
Study 15170931 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative exercise/education program (4-week duration)
Number of subjects: 131
Study 15170931 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 131
Study 11269462 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin (2 x 10(6) kallikrein inhibitor units)
Number of subjects: 100
Study 11269462 — intervention group
Group type: COMPARATOR
Intervention: Epsilon aminocaproic acid (EACA) (20 g)
Number of subjects: 100
Study 11269462 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin
Number of subjects: 100
Study 11269462 — intervention group
Group type: COMPARATOR
Intervention: Epsilon aminocaproic acid (EACA)
Number of subjects: 100
Study 9505147 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment for 12 weeks
Number of subjects: 60
Study 9505147 — intervention group
Group type: COMPARATOR
Intervention: Control group (diet and lifestyle advice and lovastatin 40 mg/dag during a 4-week run-in period)
Number of subjects: 60
Study 9505147 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-obese patients receiving Metformin
Number of subjects: 60
Study 8141225 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapartum chemoprophylaxis
Number of subjects: 9
Study 8141225 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 9
Study 2643167 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 10 to 20 mg once daily
Number of subjects: 12
Study 2643167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 125147 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptozotocin (0.5 g/m IV weekly)
Number of subjects: 197
Study 125147 — intervention group
Group type: EXPERIMENTAL
Intervention: CCNU (130 mg/m orally every 6 weeks)
Number of subjects: 197
Study 125147 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-Thioguanine (1.0 mg/kg/day orally)
Number of subjects: 197
Study 125147 — intervention group
Group type: EXPERIMENTAL
Intervention: Procarbazine (3 mg/kg/day orally)
Number of subjects: 197
Study 30745073 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 150
Study 30745073 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine
Number of subjects: 150
Study 30745073 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey
Number of subjects: 150
Study 27879567 — intervention group
Group type: EXPERIMENTAL
Intervention: Collar-fixation (CF) group - postoperative Philadelphia collar for 2 weeks
Number of subjects: 74
Study 27879567 — intervention group
Group type: COMPARATOR
Intervention: No-collar (NC) group
Number of subjects: 74
Study 27879567 — intervention group
Group type: EXPERIMENTAL
Intervention: Collar-fixation (CF) group
Number of subjects: 74
Study 26126178 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal prevention intervention
Number of subjects: 1874
Study 23867417 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency (1 Hz) rTMS applied for 20 min per day over 10 days
Number of subjects: 12
Study 23867417 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 12
Study 21807138 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert Patient Programme (EPP) plus usual care
Number of subjects: 64
Study 21807138 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 64
Study 19249421 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 3
Study 19249421 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 3
Study 15920566 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 ml lignocaine 2% with sodium hyaluronidase 75 IU/ml (Group B)
Number of subjects: 60
Study 15920566 — intervention group
Group type: COMPARATOR
Intervention: 4 ml lignocaine 2% (Group A)
Number of subjects: 60
Study 15287198 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate-buffered replacement fluid
Number of subjects: 8
Study 15287198 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate-buffered replacement fluid
Number of subjects: 8
Study 11239280 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Research Arm (ARA) test
Number of subjects: 20
Study 9570604 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 100 mg
Number of subjects: 12
Study 9570604 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 15 mg
Number of subjects: 12
Study 9570604 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine 15 mg
Number of subjects: 12
Study 8072050 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methadone (80 mg)
Number of subjects: 38
Study 8072050 — intervention group
Group type: COMPARATOR
Intervention: Low-dose methadone (40 mg)
Number of subjects: 38
Study 8072050 — intervention group
Group type: EXPERIMENTAL
Intervention: Both high-dose and low-dose methadone
Number of subjects: 38
Study 2468872 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg single oral daily dose for a 3‐week treatment period)
Number of subjects: 20
Study 2468872 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 20
Study 31519680 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced community case management (CCM) plus monthly screening and treatment (MSAT) using rapid diagnostic tests (RDTs)
Number of subjects: 180
Study 31519680 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care plus enhanced CCM, comprising active weekly screening for fever and detection and treatment of infections in fever positive individuals using RDTs
Number of subjects: 180
Study 31519680 — intervention group
Group type: COMPARATOR
Intervention: Current standard of care with passively monitored malaria infections
Number of subjects: 180
Study 28738788 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate for 6 hours postpartum
Number of subjects: 284
Study 28738788 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulfate for 24 hours postpartum
Number of subjects: 284
Study 26711317 — intervention group
Group type: EXPERIMENTAL
Intervention: rAAV2-NRTN
Number of subjects: 53
Study 25349302 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen plus ovarian function suppression (OFS)
Number of subjects: 345
Study 25349302 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 345
Study 22537222 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month intervention consisting of tailored obesogenic behavior change goals, self-monitoring via interactive voice response phone calls, tailored skills training materials, 12 counseling calls with a registered dietitian, and a 12-month YMCA membership.
Number of subjects: 194
Study 22537222 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 194
Study 20006254 — intervention group
Group type: EXPERIMENTAL
Intervention: Group S7.5 (1.5 mL of 0.5% hyperbaric bupivacaine)
Number of subjects: 152
Study 20006254 — intervention group
Group type: EXPERIMENTAL
Intervention: Group S5 (1.0 mL of 0.5% hyperbaric bupivacaine)
Number of subjects: 152
Study 20006254 — intervention group
Group type: EXPERIMENTAL
Intervention: Group S4 (0.8 mL of 0.5% hyperbaric bupivacaine)
Number of subjects: 152
Study 17326076 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated framework for identifying regions of anatomical abnormality in MR images and using them as seed points for fiber tracking with DTI.
Number of subjects: 0
Study 17326076 — intervention group
Group type: COMPARATOR
Intervention: Automated algorithm for volume-preserved warping (VPW) and fiber tracking.
Number of subjects: 0
Study 15125183 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily
Number of subjects: 60
Study 15125183 — intervention group
Group type: COMPARATOR
Intervention: Dorzolamide 2% three times daily
Number of subjects: 60
Study 15125183 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both interventions
Number of subjects: 60
Study 11213002 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage repair leaving the skin unsutured
Number of subjects: 793
Study 11213002 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglactin 910
Number of subjects: 793
Study 11213002 — intervention group
Group type: COMPARATOR
Intervention: Standard three-stage repair
Number of subjects: 793
Study 11213002 — intervention group
Group type: COMPARATOR
Intervention: Chromic catgut
Number of subjects: 793
Study 9751631 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytarabine (3 g/m2)
Number of subjects: 285
Study 9751631 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose cytarabine (400 mg/m2)
Number of subjects: 285
Study 9751631 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cytarabine (100 mg/m2)
Number of subjects: 285
Study 9751631 — intervention group
Group type: COMPARATOR
Intervention: All doses of cytarabine
Number of subjects: 285
Study 7851109 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial data entry
Number of subjects: 44
Study 7851109 — intervention group
Group type: COMPARATOR
Intervention: Double data entry
Number of subjects: 44
Study 7851109 — intervention group
Group type: EXPERIMENTAL
Intervention: Vital/important error rate
Number of subjects: 44
Study 3289550 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (15 mg)
Number of subjects: 30
Study 3289550 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.5 mg)
Number of subjects: 30
Study 3289550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31975496 — intervention group
Group type: EXPERIMENTAL
Intervention: Istaroxime 0.5 μg/kg/min
Number of subjects: 99
Study 31975496 — intervention group
Group type: EXPERIMENTAL
Intervention: Istaroxime 1.0 μg/kg/min
Number of subjects: 99
Study 31975496 — intervention group
Group type: EXPERIMENTAL
Intervention: Istaroxime (both doses)
Number of subjects: 99
Study 31975496 — intervention group
Group type: COMPARATOR
Intervention: Istaroxime and placebo (all groups)
Number of subjects: 99
Study 31975496 — intervention group
Group type: COMPARATOR
Intervention: Istaroxime and placebo
Number of subjects: 99
Study 30944022 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial managers' unguided recruitment predictions
Number of subjects: 56
Study 30944022 — intervention group
Group type: EXPERIMENTAL
Intervention: Red flags for recruitment failure identified by trial managers
Number of subjects: 56
Study 26850796 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial acupuncture
Number of subjects: 41
Study 26850796 — intervention group
Group type: COMPARATOR
Intervention: Facial/body acupuncture
Number of subjects: 41
Study 24418042 — intervention group
Group type: EXPERIMENTAL
Intervention: One-on-one teaching (1-1)
Number of subjects: 16
Study 24418042 — intervention group
Group type: COMPARATOR
Intervention: Group teaching (GT)
Number of subjects: 16
Study 24418042 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (1-1 and GT)
Number of subjects: 16
Study 22568569 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized cognitive counseling (PCC)
Number of subjects: 374
Study 22568569 — intervention group
Group type: COMPARATOR
Intervention: Standard risk-reduction counseling (control)
Number of subjects: 374
Study 20798194 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (10,000 IU 3 times weekly)
Number of subjects: 223
Study 20798194 — intervention group
Group type: COMPARATOR
Intervention: Best standard care (BSC)
Number of subjects: 223
Study 18756431 — intervention group
Group type: EXPERIMENTAL
Intervention: 17alpha-hydroxyprogesterone caproate (17P), 341 mg intramuscularly, twice a week until 36 weeks
Number of subjects: 45
Study 18756431 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 45
Study 18756431 — intervention group
Group type: EXPERIMENTAL
Intervention: 17alpha-hydroxyprogesterone caproate (17P)
Number of subjects: 45
Study 15811049 — intervention group
Group type: EXPERIMENTAL
Intervention: Listerine Antiseptic (30 s rinse)
Number of subjects: 40
Study 15811049 — intervention group
Group type: COMPARATOR
Intervention: Sterile water control (30 s rinse)
Number of subjects: 40
Study 15811049 — intervention group
Group type: EXPERIMENTAL
Intervention: Listerine Antiseptic (60 min post rinse follow-up)
Number of subjects: 40
Study 12835206 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplant vasculopathy subjects
Number of subjects: 15
Study 12835206 — intervention group
Group type: COMPARATOR
Intervention: No angiographic evidence of disease subjects
Number of subjects: 15
Study 10925686 — intervention group
Group type: EXPERIMENTAL
Intervention: HCFU 100 mg
Number of subjects: 0
Study 10925686 — intervention group
Group type: COMPARATOR
Intervention: 5-FU 250 mg
Number of subjects: 0
Study 10925686 — intervention group
Group type: COMPARATOR
Intervention: 5-FU 500 mg
Number of subjects: 0
Study 8893355 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant inflow (CFlow) administration
Number of subjects: 7
Study 8893355 — intervention group
Group type: COMPARATOR
Intervention: Constant fraction (CF) administration
Number of subjects: 7
Study 8457158 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative infection
Number of subjects: 0
Study 8457158 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative fever without documented infection
Number of subjects: 0
Study 8457158 — intervention group
Group type: EXPERIMENTAL
Intervention: Infected patients
Number of subjects: 0
Study 8457158 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of departmental cost‐charge ratios
Number of subjects: 0
Study 2431395 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymostimulin (TP‐1 Serono: 1.5 mg/kg/die for five days)
Number of subjects: 28
Study 2431395 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 28
Study 2431395 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymostimulin (TP‐1 Serono)
Number of subjects: 28
Study 30111357 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06410293
Number of subjects: 597
Study 30111357 — intervention group
Group type: COMPARATOR
Intervention: adalimumab-EU
Number of subjects: 597
Study 24076045 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic bicycling exercises
Number of subjects: 80
Study 24076045 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity aerobic bicycling exercises
Number of subjects: 80
Study 24076045 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric muscle contraction exercises (arm and leg)
Number of subjects: 80
Study 24076045 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor tests (hand and foot)
Number of subjects: 80
Study 24076045 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (general)
Number of subjects: 80
Study 24076045 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor tests (general)
Number of subjects: 80
Study 24076045 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned pain modulation (CPM)
Number of subjects: 80
Study 22539584 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose challenge (75-g glucose tolerance test)
Number of subjects: 59
Study 20077149 — intervention group
Group type: EXPERIMENTAL
Intervention: Family intervention (three-session family intervention)
Number of subjects: 173
Study 20077149 — intervention group
Group type: COMPARATOR
Intervention: Mailers to engage families
Number of subjects: 173